Quick SummaryRetatrutide is a triple agonist (GLP-1 + GIP + Glucagon), while Tirzepatide is dual (GLP-1 + GIP).
Retatrutide shows superior fat loss in trials — up to 24% total body weight vs 21% with Tirzepatide.
Both are long-acting and dosed weekly, but Retatrutide may offer greater energy expenditure and thermogenesis.
Peptides Lab UK…
Quick SummaryRetatrutide is a triple agonist peptide (GLP-1, GIP, Glucagon) under active clinical investigation.
Preclinical and Phase II trial data show dose-dependent fat loss, metabolic, and appetite-regulation effects.
Titration protocols start at 1mg/week and escalate gradually — skipping steps increases adverse event risk.
Peptides Lab UK offers HPLC-verified, COA-confirmed Retatrutide in lyophilised vials for…
